Zacks: Analysts Anticipate CRISPR THERAPTC (CRSP) Will Post Quarterly Sales of $2.05 Million - StockNewsTimes

Zacks: Analysts Anticipate CRISPR THERAPTC (CRSP) Will Post Quarterly Sales of $2.05 Million StockNewsTimes CRISPR THERAPTC logo Wall Street analysts expect CRISPR THERAPTC (NASDAQ:CRSP) to report sales of $2.05 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for CRISPR THERAPTC's ... and more »

from Health - Google News http://ift.tt/2xbi56y